
Merck CEO Rob Davis
Merck, wading even further into rare disease, inks $11.5B deal for Acceleron and its potential PAH blockbuster
Confirming days of rumors and insider leaks, Merck will acquire Acceleron Pharma and its lead PAH drug sotatercept for $11.5 billion, the companies said Thursday.
The acquisition doesn’t come at much of a premium: Shares of $XLRN closed Wednesday at around $175, suspiciously plummeting from a high of around $186 earlier in the day. The company’s stock had ticked up for days after reports from Bloomberg and the Wall Street Journal quoting insider sources mostly outlined the terms of the deal with Merck.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters